We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...
Gov. Kathy Hochul on Tuesday announced a $150 million investment in a new state-of-the-art cell and gene therapy hub to be ...
Gov. Kathy Hochul on Tuesday announced a $150 million investment in the new state-of-the-art therapy hub to be built on ...
The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for ...
Sangamo (SGMO) announced the outcome of a recent interaction with the FDA, providing a clear regulatory pathway to accelerated approval for ...
Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...
The first patient to undergo recently approved gene therapy for sickle cell disease, Kendric Cromer, has left the hospital.
A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...
The National Institutes of Health has awarded an assistant professor of biomedical engineering about $1.8 million to study ...
The Blumberg Institute, a nonprofit biotechnology research and education organization focused on finding a cure for hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback